Skip to main content

Dr. Thomas Ortel, M.D.

Hematology (Hematology (Internal Medicine) Physician)

  • Medicare participating

At a glance

Years since graduation
41
In the NPI registry since
2006
Medicare patients seen, 2024
191

The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is

Education and training

  • 1985Medical school: Indiana University School of Medicine
  • 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier

Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).

Specialties and state licenses

  • Hematology (Internal Medicine) Physician primary
    NC license 37916

As reported to the NPI registry. To confirm a license is current, check the state medical board.

Map: Hematology per capita by county →

Where they work

Hospitals

Medical groups

Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.

Medicare patients and services

Medicare patients, 2024
191
Services billed
363
Patients’ average age
69
Most frequent Medicare services, 2023
ServiceTimesPatients
Coagulation function screening test with interpretation and report8362
Established patient office or other outpatient visit, 30-39 minutes5653
Established patient office or other outpatient visit, 20-29 minutes2121
New patient office or other outpatient visit, 45-59 minutes1313

Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.

Medicare prescriptions

Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.

Payments from drug and device companies

In 2025, 2 companies reported 7 payments worth $28,788 in total to this clinician.

By company
F. Hoffmann-la Roche AG$24,108
Alexion Pharmaceuticals, Inc.$4,680
By type
Consulting Fee$16,750
Travel and Lodging$11,840
Food and Beverage$198

What the payments were for

Largest payments other than meals
DateCompanyWhat it was forAmount
May 6, 2025F. Hoffmann-la Roche AG
May 6, 2025
Travel and Lodging
travel to London, Great Britain (UK)
$11,374
May 6, 2025F. Hoffmann-la Roche AG
May 6, 2025
Consulting Fee$8,790
Nov 19, 2025Alexion Pharmaceuticals, Inc.
Nov 19, 2025
Consulting Fee$4,680
May 19, 2025F. Hoffmann-la Roche AG
May 19, 2025
Consulting Fee$3,280
May 6, 2025F. Hoffmann-la Roche AG
May 6, 2025
Travel and Lodging
travel to London, Great Britain (UK)
$373
May 6, 2025F. Hoffmann-la Roche AG
May 6, 2025
Travel and Lodging
travel to London, Great Britain (UK)
$93.33

Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.

From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.

Who received the most in North Carolina →

Industry-funded research

Named as a principal investigator on 4 industry-funded studies in 2025, from 2 companies. The companies reported $443,001 in research payments for these studies, mostly to the institutions running them.

  • A Study of BAX 930 in Children, Teenagers, and Adults Born With Thrombotic Thrombocytopenic Purpura (TTP)
    Takeda Pharmaceuticals U.S.A., Inc. · Completed · NCT03393975
  • A phase 3B, prospeca phase 3B, prospective, open-label, multicenter, single treatment arm, continuation study of the safety and efficacy of TAK-755 (RADAMTS-13, also known as bax 930/SHP655) in the prophylactic and on…
    Takeda Pharmaceuticals U.S.A., Inc.
  • Study name not reported
    Instrumentation Laboratory Company
  • A study of TAK-755 (RADAMTS13) with little to no plasma exchange (pex) treatment in adults with immune-mediated thrombotic thrombocytopenic purpura (ittp)
    Takeda Pharmaceuticals U.S.A., Inc.

From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.

Other Hematology clinicians in Durham

Sources

NPI registry (CMS NPPES, November 2026; record last updated November 14, 2007), Medicare Care Compare, Medicare Physician & Other Practitioners (2024), Medicare Part D Prescribers (2024) and Open Payments (2025). Information is self-reported or billed data and may be out of date; call before visiting.

NPI 1003990995. Official NPI registry record (opens in a new tab). Clinicians can correct their information in NPPES; changes appear here after our next monthly update.